Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesGeneration of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.Model-based design of growth-attenuated virusesRefined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virusA single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1βComplementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.Nonsegmented negative-strand viruses as vaccine vectors.Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.Development and Applications of VSV Vectors Based on Cell TropismCreation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectorsNeurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesVesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirusThe immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.Progress in filovirus vaccine development: evaluating the potential for clinical use.Carriers for the delivery of a vaccine against respiratory syncytial virus.Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceA chimeric vesiculo/alphavirus is an effective alphavirus vaccineHexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.RNA replicons - a new approach for influenza virus immunoprophylaxis.
P2860
Q21090120-DD6240E0-766A-421A-B25B-45AF6B175552Q21131585-C7DE2D35-BCFD-4FD5-93B8-C07436ADB575Q27472940-1BE1BF1D-E38D-4FE6-80DA-217A68050F4AQ27473287-8E918E70-8871-4D95-BCED-F2CBC8E9F2B9Q30361939-DA5ECC8C-7E39-4128-9B20-3923E44C00A5Q30370147-16AF7769-AFA4-42AC-8FC0-ED4E8804979FQ30385999-AFA4C834-4879-4170-83D6-0F7E55893BACQ33256104-CA807508-181C-4584-B485-51598F85928EQ33721746-CFFEACD8-6931-4756-A876-BF7197C23EABQ33725635-88157493-886F-4E91-B82D-FBE55C439A60Q33743852-FE16280B-CB5D-4014-A6C4-4CE4EFC92A45Q33752841-021B5FC4-6AD8-4874-810F-B8E29450A591Q34092753-DA4BB5F4-B44F-474F-ACBB-15FDDB1019E9Q34441577-78813196-8247-42A4-A5AD-E205302B12A8Q34741896-F0ABE5B8-05E4-4015-ABCF-DCBF00DC3041Q34742846-8538A1D3-5231-47F6-B2E6-6EEF9F6EC6ADQ35076920-BCF84E54-BE1C-4581-86A8-D566C0082264Q35139219-3F009328-95E4-4BA7-9607-91AAD7E42041Q35182301-EDED1C31-F5CA-432E-9176-7DC59FE3FD02Q35635393-32B43E44-4F98-4370-9C01-6F498908326AQ35679152-859C55E3-8ECD-48D1-8093-669F30E8B198Q35760520-9E6505D6-4A21-451C-9FEF-7DCA7895CEF1Q35781967-654473E6-5178-4C7F-AC46-5B43BB61842FQ35857789-D0560092-5F4F-4E92-A238-0988E6C59EBCQ35867988-43CD45BB-23BA-4C63-BC11-F00B87C39892Q36043290-D2FA66BB-A96D-40AA-A589-EC81D3A2A557Q36100545-50C56158-83E6-4728-8F99-C181E7AB047BQ36194078-8B34D3D7-5FB9-4419-8963-575593FE3029Q36315159-3BBDA278-2188-4BAC-BB9B-3FC467B038C0Q36423935-4C0464AF-6779-45A3-9C47-FA711FD0BDB6Q36506753-AB4A96A8-D618-45D7-862B-43E2251CAEE4Q36659279-74833AFD-B2AD-4BCC-BCD2-A64B271F6DABQ37066697-FFB4899F-0E31-4D46-B4A1-2E761E1A9152Q37243886-762E0488-D922-4CCB-9DBE-BFF8033654ADQ37348721-37D6DAC9-B65D-4A97-9B56-35E768F1D48CQ37355979-51960BCF-9872-4E02-A46C-851D69790B63Q37418736-F6D7E9F2-DB50-464A-BB71-E262B3F72122Q37427047-2351C395-8D8F-4D38-A65F-FFBC25519697Q37455765-F81E0674-09B1-497E-B192-47B565875EC2Q37945198-003D6A5B-BB3F-4EEB-A369-D4902C2E52E1
P2860
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Replication-competent or atten ...... ct mice against RSV challenge.
@ast
Replication-competent or atten ...... ct mice against RSV challenge.
@en
type
label
Replication-competent or atten ...... ct mice against RSV challenge.
@ast
Replication-competent or atten ...... ct mice against RSV challenge.
@en
prefLabel
Replication-competent or atten ...... ct mice against RSV challenge.
@ast
Replication-competent or atten ...... ct mice against RSV challenge.
@en
P2093
P2860
P1433
P1476
Replication-competent or atten ...... ct mice against RSV challenge.
@en
P2093
P2860
P304
11079-11087
P356
10.1128/JVI.75.22.11079-11087.2001
P577
2001-11-01T00:00:00Z